Teriflunomide Tablet, Film Coated
Product Images NDC 62332-314

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 62332-314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

14 mg Per Tablet (Teriflunomide 14 mg Carton2)

Packaging label for Teriflunomide Tablets 14 mg oral film-coated tablets by Alembic Pharmaceuticals Inc. The carton contains 28 unit-dose tablets (2 blister packs of 14 tablets each). The label includes the NDC number 62332-314-28 and instructions for pharmacists to dispense a Medication Guide. The design features a blue and green stripe with the Alembic logo.*

FDA Label Image

Teriflunomide-14mg-30bl.jpg (Teriflunomide 14mg 30bl)

Label for Teriflunomide Tablets, 14 mg per tablet, oral film-coated tablets. The label shows the NDC 62332-314-30 and states a package quantity of 30 tablets. It includes the manufacturer Alembic Pharmaceuticals Limited, Gujarat, India, and Alembic Pharmaceuticals, Inc., Bedminster, NJ. The label also provides storage instructions and a pharmacist dispensing advisory.*

FDA Label Image

14 mg Per Tablet (Teriflunomide 14mg Wallet Card)

Teriflunomide Tablets 14 mg film-coated oral tablets packaged in a blister pack. The label shows a total count of 28 tablets with instructions for dispensing including a Medication Guide. The product is labeled as prescription only and manufactured by Alembic Pharmaceuticals Inc. The packaging includes a detailed folding insert with opening instructions.*

FDA Label Image

7 mg Per Tablet (Teriflunomide 7 mg Carton2)

Teriflunomide Tablets 7 mg film-coated oral tablets carton label. The label shows the dosage strength of 7 mg per tablet, with a package quantity of 28 tablets in unit-dose format (2 x 14). Alembic Pharmaceuticals Inc. is listed as the labeler. Packaging includes dosage instructions and pharmacist dispensing information.*

FDA Label Image

Teriflunomide-7mg-30bl.jpg (Teriflunomide 7mg 30bl)

Label for Teriflunomide Tablets 7 mg, film-coated oral tablets by Alembic Pharmaceuticals Inc. The label states each tablet contains 7 mg teriflunomide, and the package contains 30 tablets. Instructions note usual dosage is one tablet once daily. The label includes NDC 62332-313-30, manufacturer details for Alembic Pharmaceuticals Limited in India and Alembic Pharmaceuticals, Inc. in the USA, and a dispenser instruction to provide the Medication Guide to patients.*

FDA Label Image

7 mg Per Tablet (Teriflunomide 7mg Wallet Card)

Packaging label for Teriflunomide Tablets 7 mg film-coated oral tablets by Alembic Pharmaceuticals Inc. The label includes visuals of blister packs containing 28 tablets, dosing instructions, and the product name prominently displayed with strength 7 mg on the carton. The label also instructs dispensing an accompanying Medication Guide to each patient.*

FDA Label Image

14 mg Per Tablet (Teriflunomide Carton 14mg)

Packaging label for Teriflunomide Tablets 14 mg, film-coated oral tablets by Alembic Pharmaceuticals Inc. The label indicates 28 tablets per package, prescription use only, with dosage information and storage instructions. The label includes manufacturer details and a medication guide reference.*

FDA Label Image

7 mg Per Tablet (Teriflunomide Carton 7mg)

Teriflunomide Tablets 7 mg film-coated oral tablets packaging label showing a count of 28 tablets. The label includes the NDC 62332-313-14 and notes the product is Rx only. It is manufactured by Alembic Pharmaceuticals Inc. The label features dosage information, storage instructions, and a barcode.*

FDA Label Image

Fig2 (Teriflunomide Fig2)

A line graph showing the percentage of disability progression sustained for 12 weeks over a period of 108 weeks comparing placebo, 7 mg Teriflunomide tablets, and 14 mg Teriflunomide tablets. The graph includes a number-at-risk table below, indicating subject counts at various time points for each group. The 14 mg Teriflunomide group shows a statistically significant difference from placebo (p < 0.05).*

FDA Label Image

Teriflunomide-figure1.jpg (Teriflunomide Figure1)

A line graph depicting disability progression sustained over 12 weeks among three groups: Placebo, 7 mg Teriflunomide Tablets, and 14 mg Teriflunomide Tablets. The x-axis represents weeks, and the y-axis represents the percentage of disability progression. The graph includes a table showing the number of patients at risk for each group at various time points up to 108 weeks. Statistical significance is noted for the 14 mg dose compared to placebo.*

FDA Label Image

Structure (Teriflunomide Structure)

Chemical structure of Teriflunomide. The molecular diagram depicts the arrangement of carbon, hydrogen, nitrogen, oxygen, and fluorine atoms characteristic of Teriflunomide's active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.